Helen M Faddy, Carla Osiowy, Brian Custer, Michael Busch, Susan L Stramer, Melinda M Dean, Jessika Acutt, Elvina Viennet, Thijs van de Laar, Wai-Chiu Tsoi, Claire Styles, Phil Kiely, Angelo Margaritis, So-Yong Kwon, Yan Qiu, Xuelian Deng, Antoine Lewin, Signe Winther Jørgensen, Christian Erikstrup, David Juhl, Silvia Sauleda, Bernardo Armando Camacho Rodriguez, Lisbeth Jennifer Catherine Soto Coral, Paula Andrea Gaviria García, Sineenart Oota, Sheila F O'Brien, Silvano Wendel, Emma Castro, Laura Navarro Pérez, Heli Harvala, Katy Davison, Claire Reynolds, Lisa Jarvis, Piotr Grabarczyk, Aneta Kopacz, Magdalena Łętowska, Niamh O'Flaherty, Fiona Young, Padraig Williams, Lisa Burke, Sze Sze Chua, An Muylaert, Isabel Page, Ann Jones, Christoph Niederhauser, Marion Vermeulen, Syria Laperche, Pierre Gallian, Masahiro Satake, Marcelo Addas-Carvalho, Sebastián Blanco, Sandra V Gallego, Axel Seltsam, Marijke Weber-Schehl, Arwa Z Al-Riyami, Khuloud Al Maamari, Fatma Ba Alawi, Hem Chandra Pandey, Rochele Azevedo França, Richard Charlewood
{"title":"一项关于病毒核酸扩增检测(NAT)特点的国际审查显示,使用较小规模的病毒库和个人捐赠 NAT 已成为一种趋势。","authors":"Helen M Faddy, Carla Osiowy, Brian Custer, Michael Busch, Susan L Stramer, Melinda M Dean, Jessika Acutt, Elvina Viennet, Thijs van de Laar, Wai-Chiu Tsoi, Claire Styles, Phil Kiely, Angelo Margaritis, So-Yong Kwon, Yan Qiu, Xuelian Deng, Antoine Lewin, Signe Winther Jørgensen, Christian Erikstrup, David Juhl, Silvia Sauleda, Bernardo Armando Camacho Rodriguez, Lisbeth Jennifer Catherine Soto Coral, Paula Andrea Gaviria García, Sineenart Oota, Sheila F O'Brien, Silvano Wendel, Emma Castro, Laura Navarro Pérez, Heli Harvala, Katy Davison, Claire Reynolds, Lisa Jarvis, Piotr Grabarczyk, Aneta Kopacz, Magdalena Łętowska, Niamh O'Flaherty, Fiona Young, Padraig Williams, Lisa Burke, Sze Sze Chua, An Muylaert, Isabel Page, Ann Jones, Christoph Niederhauser, Marion Vermeulen, Syria Laperche, Pierre Gallian, Masahiro Satake, Marcelo Addas-Carvalho, Sebastián Blanco, Sandra V Gallego, Axel Seltsam, Marijke Weber-Schehl, Arwa Z Al-Riyami, Khuloud Al Maamari, Fatma Ba Alawi, Hem Chandra Pandey, Rochele Azevedo França, Richard Charlewood","doi":"10.1111/vox.13617","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Nucleic acid-amplification testing (NAT) is used for screening blood donations/donors for blood-borne viruses. We reviewed global viral NAT characteristics and NAT-yield confirmatory testing used by blood operators.</p><p><strong>Materials and methods: </strong>NAT characteristics and NAT-yield confirmatory testing used during 2019 was surveyed internationally by the International Society of Blood Transfusion Working Party Transfusion-Transmitted Infectious Diseases. Reported characteristics are presented herein.</p><p><strong>Results: </strong>NAT was mainly performed under government mandate. Human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) NAT was performed on all donors and donation types, while selective testing was reported for West Nile virus, hepatitis E virus (HEV), and Zika virus. Individual donation NAT was used for HIV, HCV and HBV by ~50% of responders, while HEV was screened in mini-pools by 83% of responders performing HEV NAT. Confirmatory testing for NAT-yield samples was generally performed by NAT on a sample from the same donation or by NAT and serology on samples from the same donation and a follow-up sample.</p><p><strong>Conclusion: </strong>In the last decade, there has been a trend towards use of smaller pool sizes or individual donation NAT. We captured characteristics of NAT internationally in 2019 and provide insights into confirmatory testing approaches used for NAT-yields, potentially benefitting blood operators seeking to implement NAT.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An international review of the characteristics of viral nucleic acid-amplification testing (NAT) reveals a trend towards the use of smaller pool sizes and individual donation NAT.\",\"authors\":\"Helen M Faddy, Carla Osiowy, Brian Custer, Michael Busch, Susan L Stramer, Melinda M Dean, Jessika Acutt, Elvina Viennet, Thijs van de Laar, Wai-Chiu Tsoi, Claire Styles, Phil Kiely, Angelo Margaritis, So-Yong Kwon, Yan Qiu, Xuelian Deng, Antoine Lewin, Signe Winther Jørgensen, Christian Erikstrup, David Juhl, Silvia Sauleda, Bernardo Armando Camacho Rodriguez, Lisbeth Jennifer Catherine Soto Coral, Paula Andrea Gaviria García, Sineenart Oota, Sheila F O'Brien, Silvano Wendel, Emma Castro, Laura Navarro Pérez, Heli Harvala, Katy Davison, Claire Reynolds, Lisa Jarvis, Piotr Grabarczyk, Aneta Kopacz, Magdalena Łętowska, Niamh O'Flaherty, Fiona Young, Padraig Williams, Lisa Burke, Sze Sze Chua, An Muylaert, Isabel Page, Ann Jones, Christoph Niederhauser, Marion Vermeulen, Syria Laperche, Pierre Gallian, Masahiro Satake, Marcelo Addas-Carvalho, Sebastián Blanco, Sandra V Gallego, Axel Seltsam, Marijke Weber-Schehl, Arwa Z Al-Riyami, Khuloud Al Maamari, Fatma Ba Alawi, Hem Chandra Pandey, Rochele Azevedo França, Richard Charlewood\",\"doi\":\"10.1111/vox.13617\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>Nucleic acid-amplification testing (NAT) is used for screening blood donations/donors for blood-borne viruses. We reviewed global viral NAT characteristics and NAT-yield confirmatory testing used by blood operators.</p><p><strong>Materials and methods: </strong>NAT characteristics and NAT-yield confirmatory testing used during 2019 was surveyed internationally by the International Society of Blood Transfusion Working Party Transfusion-Transmitted Infectious Diseases. Reported characteristics are presented herein.</p><p><strong>Results: </strong>NAT was mainly performed under government mandate. Human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) NAT was performed on all donors and donation types, while selective testing was reported for West Nile virus, hepatitis E virus (HEV), and Zika virus. Individual donation NAT was used for HIV, HCV and HBV by ~50% of responders, while HEV was screened in mini-pools by 83% of responders performing HEV NAT. Confirmatory testing for NAT-yield samples was generally performed by NAT on a sample from the same donation or by NAT and serology on samples from the same donation and a follow-up sample.</p><p><strong>Conclusion: </strong>In the last decade, there has been a trend towards use of smaller pool sizes or individual donation NAT. We captured characteristics of NAT internationally in 2019 and provide insights into confirmatory testing approaches used for NAT-yields, potentially benefitting blood operators seeking to implement NAT.</p>\",\"PeriodicalId\":23631,\"journal\":{\"name\":\"Vox Sanguinis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vox Sanguinis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/vox.13617\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.13617","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
An international review of the characteristics of viral nucleic acid-amplification testing (NAT) reveals a trend towards the use of smaller pool sizes and individual donation NAT.
Background and objectives: Nucleic acid-amplification testing (NAT) is used for screening blood donations/donors for blood-borne viruses. We reviewed global viral NAT characteristics and NAT-yield confirmatory testing used by blood operators.
Materials and methods: NAT characteristics and NAT-yield confirmatory testing used during 2019 was surveyed internationally by the International Society of Blood Transfusion Working Party Transfusion-Transmitted Infectious Diseases. Reported characteristics are presented herein.
Results: NAT was mainly performed under government mandate. Human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) NAT was performed on all donors and donation types, while selective testing was reported for West Nile virus, hepatitis E virus (HEV), and Zika virus. Individual donation NAT was used for HIV, HCV and HBV by ~50% of responders, while HEV was screened in mini-pools by 83% of responders performing HEV NAT. Confirmatory testing for NAT-yield samples was generally performed by NAT on a sample from the same donation or by NAT and serology on samples from the same donation and a follow-up sample.
Conclusion: In the last decade, there has been a trend towards use of smaller pool sizes or individual donation NAT. We captured characteristics of NAT internationally in 2019 and provide insights into confirmatory testing approaches used for NAT-yields, potentially benefitting blood operators seeking to implement NAT.
期刊介绍:
Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections:
1) Transfusion - Transmitted Disease and its Prevention:
Identification and epidemiology of infectious agents transmissible by blood;
Bacterial contamination of blood components;
Donor recruitment and selection methods;
Pathogen inactivation.
2) Blood Component Collection and Production:
Blood collection methods and devices (including apheresis);
Plasma fractionation techniques and plasma derivatives;
Preparation of labile blood components;
Inventory management;
Hematopoietic progenitor cell collection and storage;
Collection and storage of tissues;
Quality management and good manufacturing practice;
Automation and information technology.
3) Transfusion Medicine and New Therapies:
Transfusion thresholds and audits;
Haemovigilance;
Clinical trials regarding appropriate haemotherapy;
Non-infectious adverse affects of transfusion;
Therapeutic apheresis;
Support of transplant patients;
Gene therapy and immunotherapy.
4) Immunohaematology and Immunogenetics:
Autoimmunity in haematology;
Alloimmunity of blood;
Pre-transfusion testing;
Immunodiagnostics;
Immunobiology;
Complement in immunohaematology;
Blood typing reagents;
Genetic markers of blood cells and serum proteins: polymorphisms and function;
Genetic markers and disease;
Parentage testing and forensic immunohaematology.
5) Cellular Therapy:
Cell-based therapies;
Stem cell sources;
Stem cell processing and storage;
Stem cell products;
Stem cell plasticity;
Regenerative medicine with cells;
Cellular immunotherapy;
Molecular therapy;
Gene therapy.